Browsing Tag
Ulcerative colitis
30 posts
Microbiome company Vedanta Biosciences raises $68m in Series D
Vedanta Biosciences, a clinical-stage microbiome company founded by PureTech Health, has raised $68 million in a Series D…
July 21, 2021
Merck to acquire US biotech company Pandion Therapeutics for $1.8bn
Merck has agreed to acquire Pandion Therapeutics, a Massachusetts-based clinical-stage biotech company, for about $1.85 billion in an…
February 25, 2021
ExeGi Pharma’s EXE-346 receives FDA orphan drug designation for pouchitis treatment
ExeGi Pharma, a biotechnology company headquartered in Rockville, Maryland, has announced that its live biotherapeutic product (LBP), EXE-346,…
November 15, 2020
Seres Therapeutics begins Phase 1b trial for SER-301 in active ulcerative colitis
Seres Therapeutics, a prominent US-based biotech company, has announced the commencement of dosing in a Phase 1b clinical…
November 8, 2020
Bristol Myers Squibb’s Zeposia shows promising results in phase 3 True North trial for ulcerative colitis treatment
Bristol Myers Squibb (BMS) has reported significant success in its phase 3 True North clinical trial, evaluating the…
October 11, 2020
Allergan to sell brazikumab to AstraZeneca and Zenpep to Nestle
Allergan has agreed to sell IL-23 inhibitor brazikumab to AstraZeneca and gastrointestinal medication Zenpep (pancrelipase) to Nestle in…
January 27, 2020
Janssen bags Stelara FDA approval for ulcerative colitis treatment
Stelara FDA approval for ulcerative colitis treatment : The Janssen Pharmaceutical Companies of Johnson & Johnson has bagged…
October 22, 2019
Teva launches generic version of Delzicol delayed-release capsules in US
Israeli pharma company Teva Pharmaceuticals has launched a generic version of Delzicol (mesalamine) 400mg delayed-release capsules in the…
May 19, 2019
Amgen submits BLA for Infliximab biosimilar ABP 710 to FDA
Amgen Inc. has officially submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)…
December 18, 2018
Novartis’ Sandoz gains EC approval for biosimilar Hyrimoz across multiple therapeutic areas
In a significant advancement for biopharmaceuticals, Novartis’ division Sandoz has secured approval from the European Commission (EC) for…
July 29, 2018